FY2025 EPS Estimates for STERIS plc (NYSE:STE) Increased by Zacks Research

STERIS plc (NYSE:STE) – Research analysts at Zacks Research increased their FY2025 earnings per share (EPS) estimates for STERIS in a research report issued on Wednesday, September 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $8.87 for the year, up from their prior forecast of $8.85. The consensus estimate for STERIS’s current full-year earnings is $9.06 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.52 EPS, Q4 2026 earnings at $2.59 EPS, FY2026 earnings at $9.47 EPS and FY2027 earnings at $10.01 EPS.

A number of other equities analysts also recently issued reports on the company. JMP Securities reissued a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. Stephens reissued an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. KeyCorp increased their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $246.00.

STERIS Stock Performance

STE stock opened at $235.78 on Monday. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The business’s fifty day simple moving average is $237.79 and its two-hundred day simple moving average is $225.73. STERIS has a twelve month low of $195.47 and a twelve month high of $248.24. The firm has a market cap of $23.25 billion, a price-to-earnings ratio of 61.72 and a beta of 0.83.

STERIS (NYSE:STE) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the firm posted $2.00 earnings per share. The business’s revenue was down .4% compared to the same quarter last year.

Institutional Investors Weigh In On STERIS

Several institutional investors have recently added to or reduced their stakes in the business. 9258 Wealth Management LLC raised its stake in shares of STERIS by 49.6% in the fourth quarter. 9258 Wealth Management LLC now owns 2,040 shares of the medical equipment provider’s stock worth $448,000 after purchasing an additional 676 shares during the last quarter. Bank of Nova Scotia raised its stake in shares of STERIS by 44.2% in the fourth quarter. Bank of Nova Scotia now owns 12,262 shares of the medical equipment provider’s stock worth $2,696,000 after purchasing an additional 3,756 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in STERIS during the fourth quarter valued at approximately $227,000. California State Teachers Retirement System lifted its holdings in STERIS by 1.5% in the fourth quarter. California State Teachers Retirement System now owns 154,699 shares of the medical equipment provider’s stock valued at $34,011,000 after acquiring an additional 2,361 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new position in STERIS in the fourth quarter valued at approximately $414,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity at STERIS

In related news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now owns 582 shares of the company’s stock, valued at $139,493.76. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at approximately $139,493.76. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were given a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a yield of 0.97%. This is an increase from STERIS’s previous quarterly dividend of $0.52. STERIS’s dividend payout ratio (DPR) is presently 59.69%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.